Header

UZH-Logo

Maintenance Infos

Analysis of drug-drug interactions in Swiss claims data using tizanidine and ciprofloxacin as a prototypical contraindicated combination


Jödicke, Annika M; Curkovic, Ivanka; Zellweger, Urs; Tomka, Ivan T; Neuer, Thomas; Kullak-Ublick, Gerd A; Roos, Malgorzata; Egbring, Marco (2018). Analysis of drug-drug interactions in Swiss claims data using tizanidine and ciprofloxacin as a prototypical contraindicated combination. The Annals of Pharmacotherapy, 52(10):983-991.

Abstract

BACKGROUND: Potential drug-drug interactions (pDDIs) are described in various case reports, but few studies have evaluated the impact of specific combinations on a population level.
OBJECTIVE: To analyze the type and frequency of multiple contraindicated (X-pDDIs) and major interactions (D-pDDIs) and to subsequently assess the impact of the particular combination of tizanidine and ciprofloxacin on outpatient physician visits and hospitalizations.
METHODS: Anonymized Swiss claims data from 524 797 patients in 2014-2015 were analyzed. First, frequencies of X- and D-pDDIs were calculated. Next, a retrospective cohort study was conducted among patients prescribed tizanidine and ciprofloxacin (exposed, n = 199) or tizanidine and other antibiotics (unexposed, n = 960). Hospitalizations and outpatient physician visits within 7, 14, and 30 days after initiation of antibiotic therapy were evaluated using multiple binary logistic regression and multiple linear regression.
RESULTS: The relative frequencies of X- and D-pDDIs were 0.4% and 6.65%, respectively. In the cohort study, significant associations between exposure to tizanidine and ciprofloxacin and outpatient physician visits were identified for 14 and 30 days (odds ratio [OR] = 1.61 [95% CI = 1.17-2.24], P = 0.004, and OR = 1.59 [95% CI = 1.1-2.34], P = 0.016). A trend for increased risk of hospitalization was found for all evaluated time periods (OR = 1.68 [95% CI = 0.84-3.17], OR = 1.52 [95% CI = 0.63-3.33], and OR = 2.19 [95% CI = 0.88-5.02]).
CONCLUSION and RELEVANCE: The interaction between tizanidine and ciprofloxacin is not only relevant for individual patients, but also at the population level. Further investigation of the impact of other clinically relevant DDIs is necessary to improve patient safety and reduce avoidable health care utilization.

Abstract

BACKGROUND: Potential drug-drug interactions (pDDIs) are described in various case reports, but few studies have evaluated the impact of specific combinations on a population level.
OBJECTIVE: To analyze the type and frequency of multiple contraindicated (X-pDDIs) and major interactions (D-pDDIs) and to subsequently assess the impact of the particular combination of tizanidine and ciprofloxacin on outpatient physician visits and hospitalizations.
METHODS: Anonymized Swiss claims data from 524 797 patients in 2014-2015 were analyzed. First, frequencies of X- and D-pDDIs were calculated. Next, a retrospective cohort study was conducted among patients prescribed tizanidine and ciprofloxacin (exposed, n = 199) or tizanidine and other antibiotics (unexposed, n = 960). Hospitalizations and outpatient physician visits within 7, 14, and 30 days after initiation of antibiotic therapy were evaluated using multiple binary logistic regression and multiple linear regression.
RESULTS: The relative frequencies of X- and D-pDDIs were 0.4% and 6.65%, respectively. In the cohort study, significant associations between exposure to tizanidine and ciprofloxacin and outpatient physician visits were identified for 14 and 30 days (odds ratio [OR] = 1.61 [95% CI = 1.17-2.24], P = 0.004, and OR = 1.59 [95% CI = 1.1-2.34], P = 0.016). A trend for increased risk of hospitalization was found for all evaluated time periods (OR = 1.68 [95% CI = 0.84-3.17], OR = 1.52 [95% CI = 0.63-3.33], and OR = 2.19 [95% CI = 0.88-5.02]).
CONCLUSION and RELEVANCE: The interaction between tizanidine and ciprofloxacin is not only relevant for individual patients, but also at the population level. Further investigation of the impact of other clinically relevant DDIs is necessary to improve patient safety and reduce avoidable health care utilization.

Statistics

Citations

Altmetrics

Downloads

23 downloads since deposited on 08 Aug 2018
23 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
04 Faculty of Medicine > University Hospital Zurich > Clinic for Clinical Pharmacology and Toxicology
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:ciprofloxacin, drug interactions, drug safety, health care utilization, muscle relaxants, pharmacoepidemiology
Language:English
Date:2018
Deposited On:08 Aug 2018 13:54
Last Modified:28 Dec 2018 05:24
Publisher:Harvey Whitney Books Company
ISSN:1060-0280
OA Status:Green
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.1177/1060028018775914
PubMed ID:29749261

Download

Download PDF  'Analysis of drug-drug interactions in Swiss claims data using tizanidine and ciprofloxacin as a prototypical contraindicated combination'.
Preview
Content: Accepted Version
Language: English
Filetype: PDF
Size: 321kB
View at publisher
Download PDF  'Analysis of drug-drug interactions in Swiss claims data using tizanidine and ciprofloxacin as a prototypical contraindicated combination'.
Preview
Content: Published Version
Language: English
Filetype: PDF
Size: 210kB
Licence: Creative Commons: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)